Valneva SE Sponsored ADR (NASDAQ:VALN) Given Average Recommendation of “Hold” by Analysts

Shares of Valneva SE Sponsored ADR (NASDAQ:VALN) have been assigned a consensus recommendation of “Hold” from the five analysts that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $11.9750.

VALN has been the subject of several recent analyst reports. The Goldman Sachs Group lowered Valneva from a “neutral” rating to a “sell” rating and set a $4.90 price target for the company. in a research report on Wednesday, April 22nd. Guggenheim set a $11.00 price target on Valneva in a research report on Thursday, April 16th. Finally, Wall Street Zen raised Valneva from a “strong sell” rating to a “sell” rating in a research report on Saturday.

Valneva Stock Performance

Shares of VALN stock opened at $5.68 on Friday. Valneva has a 12 month low of $5.06 and a 12 month high of $12.25. The stock has a market cap of $489.10 million, a PE ratio of -3.04 and a beta of 1.72. The company has a current ratio of 2.14, a quick ratio of 1.85 and a debt-to-equity ratio of 2.14. The company’s fifty day moving average price is $7.08 and its 200-day moving average price is $8.59.

Valneva (NASDAQ:VALN) last announced its earnings results on Tuesday, March 31st. The company reported ($0.42) EPS for the quarter. The business had revenue of $35.77 million for the quarter. Valneva had a negative net margin of 88.87% and a negative return on equity of 107.63%. On average, equities analysts expect that Valneva will post -0.81 EPS for the current fiscal year.

Institutional Investors Weigh In On Valneva

Several large investors have recently bought and sold shares of the business. Marex Group plc bought a new stake in shares of Valneva during the 2nd quarter valued at about $64,000. XTX Topco Ltd bought a new stake in shares of Valneva during the 4th quarter valued at about $94,000. JPMorgan Chase & Co. bought a new stake in shares of Valneva during the 3rd quarter valued at about $124,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Valneva during the 4th quarter valued at about $44,000. Finally, VSM Wealth Advisory LLC grew its stake in shares of Valneva by 125.0% during the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after purchasing an additional 5,000 shares during the period. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.